Table 2.
Summary of C/EBPβ expression and clinicopathological feature in the lung cancer patients.
| C/EBPβ Expression | |||||
|---|---|---|---|---|---|
| Negative n (%) |
Positive n (%) |
Total n (%) |
p Value | ||
| Sex | |||||
| Male | 23 (31) | 52 (69) | 75 (100) | 0.4343 | |
| Female | 8 (40) | 12 (60) | 20 (100) | ||
| Age | |||||
| ≤57 | 11 (31) | 24 (69) | 35 (100) | 0.8505 | |
| >57 | 20 (33) | 40 (67) | 60 (100) | ||
| Clinical Stage | |||||
| I | 10 (27) | 27 (73) | 37 (100) | 0.2305 | |
| II | 12 (32) | 25 (68) | 37 (100) | ||
| III | 9 (43) | 12 (57) | 21 (100) | ||
| N classification | |||||
| 0 | 15 (28) | 38 (72) | 53 (100) | 0.2204 | |
| 1 | 8 (33) | 16 (67) | 24 (100) | ||
| 2 | 8 (44) | 10 (66) | 18 (100) | ||
| T classification | |||||
| 1 | 1 (13) | 7 (87) | 8 (100) | 0.3039 | |
| 2 | 23 (33) | 47 (67) | 70 (100) | ||
| 3 | 5 (46) | 6 (54) | 11 (100) | ||
| 4 | 2 (33) | 4 (67) | 17 (100) | ||
| Histology | |||||
| Adenocarcinoma | 13 (46) | 15 (54) | 28 (100) | 0.0180 * | 0.0256 † |
| Squamous carcinoma | 15 (31) | 34 (69) | 49 (100) | 0.2941 # | |
| Other NSCLC | 3 (17) | 15 (83) | 18 (100) | ||
* Adenocarcinoma vs. squamous cell carcinoma, † Adenocarcinoma vs. other NSCLC, # Squamous cell carcinoma vs. other NSCLC, * † significantly different between two groups, p < 0.05. C/EBPβ staining was analyzed with 95 primary NSCLC tissues from 95 NSCLC patients.